The filing contains no financial catalyst — the stock will move on clinical/regulatory milestones, not quarterly numbers. Watch for the mid-2026 FDA meeting to confirm pivotal study design and the 2H-2026 interim Cohort 2 data readout. The $184.8M cash runway removes near-term financing risk.
Price Chart
Executive Summary
Benitec Biopharma reported Q3 fiscal 2026 results with a net loss of $11.9M ($0.24/share), narrower than the year-ago loss of $14.5M ($0.38/share). The company highlighted continued clinical progress for its lead asset BB-301 in OPMD, including durable efficacy data and safe enrollment of Cohort 2 patients, with cash of $184.8M sufficient to fund through the pivotal study. The filing is a routine quarterly update for a pre-revenue clinical-stage biotech with no revenue, no guidance, and no material financial surprises.
Key Financial Metrics
Key Facts
- Net loss of $11.9M for Q3 FY2026 vs $14.5M in Q3 FY2025, a $2.6M improvement
- EPS of $(0.24) vs $(0.38) year-ago; consensus was $(0.27) — a modest beat
- Cash and equivalents of $184.8M as of March 31, 2026, up from $97.7M at June 30, 2025
- All six Cohort 1 patients completed 12-month follow-up with robust responses to low-dose BB-301
- First two Cohort 2 patients safely treated with high-dose BB-301; no treatment-related SAEs
- FDA meeting to formalize pivotal study design expected mid-2026
- No revenue reported; company remains pre-revenue clinical-stage
- Operating expenses of $13.6M, down from $15.3M year-ago
Financial Impact
Net loss improved $2.6M YoY; cash position strengthened by $87M from prior fiscal year-end; no revenue or guidance to assess
Risk Factors
- Clinical-stage biotech with no approved products or revenue
- BB-301 pivotal study design and eventual approval remain uncertain
- Dilution risk from potential future equity offerings despite current cash position
- Competing therapies for OPMD may emerge
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-222879 |
| Document: bntc-20260514.htm | 0001193125-26-222879 |
| Document: 0001193125-26-222879-index-headers.html | 0001193125-26-222879 |
| Document: 0001193125-26-222879-index.html | 0001193125-26-222879 |
| Document: 0001193125-26-222879.txt | 0001193125-26-222879 |
| 8-K Data (Synthetic) | 0001193125-26-222879 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | DEFA14A | $8.50 $8.82 | ▲ +3.76% | ▲ +4.95% | $8.72 (+2.59%) |
Oct 20, 2026 6d ago | DEF 14A | $8.50 $8.82 | ▲ +3.76% | ▲ +4.95% | $8.72 (+2.59%) |
Oct 5, 2026 22d ago | 8-K | $9.23 $9.00 | ▼ −2.49% | ▼ −3.04% | $8.72 (−5.53%) |
Sep 30, 2026 26d ago | 8-K | $9.58 $8.98 | ▼ −6.26% | ▼ −7.00% | $8.72 (−8.98%) |
Sep 22, 2026 5w ago | EFFECT | $10.95 $9.83 | ▲ +10.23% | ▲ +9.51% | $8.72 (+20.37%) |
Sep 14, 2026 6w ago | Press Release | $11.05 $11.04 | ▼ −0.09% | ▲ +0.35% | $8.72 (−21.09%) |
Jun 11, 2026 19w ago | Institutional Cluster | $11.05 $11.18 | ▲ +1.18% | ▲ +0.64% | $8.72 (−21.09%) |
Jun 11, 2026 19w ago | Institutional Cluster | $11.05 $11.18 | ▲ +1.18% | ▲ +0.64% | $8.72 (−21.09%) |
May 14, 2026 23w ago | 8-K | $11.85 $11.49 | ▼ −3.04% | ▼ −1.81% | $8.72 (−26.41%) |
May 14, 2026 23w ago | Press Release | $11.85 $11.49 | ▼ −3.04% | ▼ −1.81% | $8.72 (−26.41%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers